New Schizophrenia Drug Development Halted
A promising new treatment for schizophrenia, pomaglumetad methionil, has been killed by is manufacturer, Eli Lilly, after less-than-stellar research results.
The drug, also known as mGlu2/3, was to be used as an adjunct to existing atypical antipsychotic medications, a commonly used type of psychiatric drug in the treatment of schizophrenia. The company looked at the results of Phase 2 research and determined it didn’t meet its primary efficacy endpoints — and was unlikely to do so given more time.
Eli Lilly denied it had anything to do with the safety profile of the drug.
This is the third drug Eli Lilly has killed this month. Pharmaceutical companies typically kill drug research programs that aren’t demonstrating the levels of effectiveness (or sometimes, safety) needed by the U.S. Food and Drug Administration in order to gain the government agency’s approval.
“I’m disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness,” said Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories.
“While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly.”
Last week, Lilly said solanezumab, a highly anticipated potential treatment for Alzheimer’s disease, failed to reach its set goals in either of two phase 3 studies
Pooled data from both studies, however, showed signs of the drug slowing cognitive decline overall in patients with mild to moderate cases of Alzheimer’s.
The company confirmed that its development pipeline still includes nearly a dozen neuroscience molecules being studied for illnesses such as depression, bipolar disorder and cognitive impairment associated with schizophrenia.
Source: Eli Lilly
News Editor, P. (2015). New Schizophrenia Drug Development Halted. Psych Central. Retrieved on November 19, 2017, from https://psychcentral.com/news/2012/08/30/new-schizophrenia-drug-development-halted/43971.html